---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-002478"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:28:00.374345+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M

## Summary
- Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).
- Gross margin improved to ~22% in Q4, up from 14% in Q3 2025.
- Q4 cash flow from operations ~$2.3M, second cash-positive quarter; cash & equivalents ~$25M at year-end.
- CEO highlighted revenue growth, increased profitability, and portfolio diversification as 2026 focus.

## SEC filing metadata
- accession: 0001628280-26-002478
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000162828026002478/0001628280-26-002478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000162828026002478/rmti-20260120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-002478
- JSON: https://secwatch.observer/filing/0001628280-26-002478.json
- Plain text: https://secwatch.observer/filing/0001628280-26-002478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.